Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2014

01-04-2014 | Review Article

Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease

Author: Nosratola D. Vaziri

Published in: Clinical and Experimental Nephrology | Issue 2/2014

Login to get access

Abstract

Advanced chronic kidney disease (CKD) results in a constellation of dysregulation of lipid metabolism, oxidative stress, and inflammation which are causally interconnected and participate in a vicious cycle. The CKD-associated lipid disorders are marked by impaired clearance of very low density lipoprotein and chylomicrons, hypertriglyceridemia, formation of small dense low-density lipoprotein (LDL), oxidative modification of LDL, intermediate density lipoprotein and chylomicron remnants, and high-density lipoprotein deficiency and dysfunction. This review provides a brief overview of the role of CKD-induced lipid disorders in the pathogenesis of oxidative stress, inflammation, cardiovascular disease, impaired exercise capacity, cachexia and wasting syndrome.
Literature
1.
go back to reference Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31:189–96.PubMedCrossRef Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31:189–96.PubMedCrossRef
2.
go back to reference Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol, Renal Physiol. 2006;290:262–72.CrossRef Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol, Renal Physiol. 2006;290:262–72.CrossRef
3.
go back to reference Vaziri ND, Moradi H. Mechanism of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10:1–7.PubMedCrossRef Vaziri ND, Moradi H. Mechanism of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10:1–7.PubMedCrossRef
4.
go back to reference Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr. 2011;21(1):120–3.PubMedCrossRef Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr. 2011;21(1):120–3.PubMedCrossRef
5.
go back to reference Rajman I, Harper L, McPake D, et al. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant. 1998;13:2281–7.PubMedCrossRef Rajman I, Harper L, McPake D, et al. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant. 1998;13:2281–7.PubMedCrossRef
6.
go back to reference Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852–62.PubMedCrossRef Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852–62.PubMedCrossRef
7.
go back to reference Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027–36.PubMed Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027–36.PubMed
8.
go back to reference Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6(5):287–96.PubMedCrossRef Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6(5):287–96.PubMedCrossRef
9.
go back to reference Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int. 1990;37:854–8.PubMedCrossRef Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int. 1990;37:854–8.PubMedCrossRef
10.
go back to reference Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928–35.PubMedCrossRef Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928–35.PubMedCrossRef
11.
go back to reference Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol. 1997;273:F925–30.PubMed Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol. 1997;273:F925–30.PubMed
12.
go back to reference Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is compounded by downregulation of endothelial GPIHBP1 expression. Clin Exp Nephrol. 2012;16:238–43.PubMedCentralPubMedCrossRef Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is compounded by downregulation of endothelial GPIHBP1 expression. Clin Exp Nephrol. 2012;16:238–43.PubMedCentralPubMedCrossRef
14.
go back to reference Kim C, Vaziri ND. Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int. 2005;67:1028–32.PubMedCrossRef Kim C, Vaziri ND. Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int. 2005;67:1028–32.PubMedCrossRef
15.
go back to reference Pahl MV, Ni Z, Sepassi L, Vaziri ND. Plasma phospholipid transfer protein, cholesterol ester transfer protein and lecithin: cholesterol acyltransferase in end-stage renal disease. Nephrol Dial Transplant. 2009;24(8):2541–6.PubMedCentralPubMedCrossRef Pahl MV, Ni Z, Sepassi L, Vaziri ND. Plasma phospholipid transfer protein, cholesterol ester transfer protein and lecithin: cholesterol acyltransferase in end-stage renal disease. Nephrol Dial Transplant. 2009;24(8):2541–6.PubMedCentralPubMedCrossRef
16.
go back to reference Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest. 1996;97:2167–73.PubMedCentralPubMedCrossRef Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest. 1996;97:2167–73.PubMedCentralPubMedCrossRef
17.
go back to reference Liang K, Vaziri ND. Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 1997;51:1933–7.PubMedCrossRef Liang K, Vaziri ND. Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 1997;51:1933–7.PubMedCrossRef
18.
go back to reference Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor deficiencies in focal glomerulosclerosis. Kidney Int. 2003;64:1780–6.PubMedCrossRef Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor deficiencies in focal glomerulosclerosis. Kidney Int. 2003;64:1780–6.PubMedCrossRef
19.
go back to reference Takahashi S, Kawarabayasi Y, Nakai T, et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA. 1992;89:9252–6.PubMedCentralPubMedCrossRef Takahashi S, Kawarabayasi Y, Nakai T, et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA. 1992;89:9252–6.PubMedCentralPubMedCrossRef
20.
go back to reference Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int. 1997;51:1761–5.PubMedCrossRef Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int. 1997;51:1761–5.PubMedCrossRef
21.
go back to reference Sato T, Liang K. VaziriND: downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int. 2002;61:157–62.PubMedCrossRef Sato T, Liang K. VaziriND: downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int. 2002;61:157–62.PubMedCrossRef
22.
go back to reference Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol (2012) pii: S0735-1097(12)04651-7. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol (2012) pii: S0735-1097(12)04651-7.
23.
go back to reference Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 2009;76(4):437–44.PubMedCentralPubMedCrossRef Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 2009;76(4):437–44.PubMedCentralPubMedCrossRef
24.
go back to reference Moradi H, Said HM, Vaziri ND Post-transcriptional nature of uremia-induced down-regulation of hepatic apolipoprotein A-I production. Transl Res PMID: 23219399, (2012). Moradi H, Said HM, Vaziri ND Post-transcriptional nature of uremia-induced down-regulation of hepatic apolipoprotein A-I production. Transl Res PMID: 23219399, (2012).
25.
go back to reference Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol. 2006;21:322–8.PubMedCrossRef Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol. 2006;21:322–8.PubMedCrossRef
26.
go back to reference Liang K, Vaziri ND. Upregulation of Acyl-CoA: cholesterol acyltransferase (ACAT) in chronic renal failure. Am J Physiol Endocrinol Metab. 2002;283:E676–81.PubMed Liang K, Vaziri ND. Upregulation of Acyl-CoA: cholesterol acyltransferase (ACAT) in chronic renal failure. Am J Physiol Endocrinol Metab. 2002;283:E676–81.PubMed
27.
go back to reference Kim HJ, Moradi H, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol. 2009;296(6):F1297–306.PubMedCentralPubMedCrossRef Kim HJ, Moradi H, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol. 2009;296(6):F1297–306.PubMedCentralPubMedCrossRef
28.
go back to reference Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic kidney disease. Am J Nephrol. 2009;30:147–54.PubMedCentralPubMedCrossRef Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic kidney disease. Am J Nephrol. 2009;30:147–54.PubMedCentralPubMedCrossRef
29.
go back to reference Vaziri ND, Bai Y, Yuan J, Said H, Sigala W, Ni Z. ApoA-1 mimetic peptide reverses uremia-induced up-regulation of pro-atherogenic pathways in the aorta. Am J Nephrol. 2010;32(3):201–11.PubMedCrossRef Vaziri ND, Bai Y, Yuan J, Said H, Sigala W, Ni Z. ApoA-1 mimetic peptide reverses uremia-induced up-regulation of pro-atherogenic pathways in the aorta. Am J Nephrol. 2010;32(3):201–11.PubMedCrossRef
30.
go back to reference Vaziri ND, Liang K, Parks JS. Downregulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192–6.PubMedCrossRef Vaziri ND, Liang K, Parks JS. Downregulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192–6.PubMedCrossRef
31.
go back to reference Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezón E, Champagne E, Pineau T, Georgeaud V, Walker JE, Tercé F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature. 2003;421:75–9.PubMedCrossRef Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezón E, Champagne E, Pineau T, Georgeaud V, Walker JE, Tercé F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature. 2003;421:75–9.PubMedCrossRef
32.
go back to reference Adams G, Vaziri ND. Skeletal muscle dysfunction in chronic renal failure: effect of exercise. Am J Physiol Renal Physiol. 2006;290:783–91. Adams G, Vaziri ND. Skeletal muscle dysfunction in chronic renal failure: effect of exercise. Am J Physiol Renal Physiol. 2006;290:783–91.
34.
go back to reference Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101:2889–95.PubMedCrossRef Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101:2889–95.PubMedCrossRef
35.
go back to reference Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef
36.
go back to reference Collins AJ, Foley R, Herzog C, et al. Excerpts from the US renal data system 2007 annual data report. Am J Kidney Dis. 2008;51:S1–320. Collins AJ, Foley R, Herzog C, et al. Excerpts from the US renal data system 2007 annual data report. Am J Kidney Dis. 2008;51:S1–320.
37.
go back to reference Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15(Suppl. 1):S77–80.PubMedCrossRef Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15(Suppl. 1):S77–80.PubMedCrossRef
38.
go back to reference Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6:723–35.PubMedCrossRef Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6:723–35.PubMedCrossRef
39.
go back to reference Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15(2):218–23.PubMedCrossRef Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15(2):218–23.PubMedCrossRef
40.
go back to reference Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome––the heart of the matter. Nephrol Dial Transplant. 2002;17(Suppl 11):28–31.PubMedCrossRef Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome––the heart of the matter. Nephrol Dial Transplant. 2002;17(Suppl 11):28–31.PubMedCrossRef
41.
go back to reference Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–9.PubMedCrossRef Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–9.PubMedCrossRef
42.
go back to reference Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303.PubMedCrossRef Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303.PubMedCrossRef
43.
go back to reference Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.PubMedCrossRef Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.PubMedCrossRef
44.
go back to reference Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.PubMedCrossRef Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.PubMedCrossRef
45.
go back to reference Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181–92.PubMedCentralPubMedCrossRef Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181–92.PubMedCentralPubMedCrossRef
Metadata
Title
Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease
Author
Nosratola D. Vaziri
Publication date
01-04-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0847-z

Other articles of this Issue 2/2014

Clinical and Experimental Nephrology 2/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.